Grants
Call for applications for early phase clinical trials in imaging and image-guided interventions
June 13, 2013
The National Cancer Institute has put out a call for applications to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling and 3D reconstruction and other quantitative tools.
The National Cancer Institute has put out a call for applications to support imaging in clinical trials.
Imaging is a vital tool in all aspects of the clinical management of cancer including screening, diagnosis, interventions, and monitoring of responses to therapy and surveillance.
Great strides have been made in the understanding of the biology and pathophysiology of cancer due to the advent of sophisticated imaging techniques. This opportunity addresses the critical need for early phase trials that accelerate the assessment of imaging modalities, methodologies and agents, as well as image-guided intervention methods through the early stages of clinical evaluation in both the general and underserved populations.
Early understanding of the effects of a given therapy or intervention could potentially allow clinicians to switch to more effective treatments saving patients from untoward side effects or death, saving both lives and resources. Early clinical trials of novel imaging agents and methodologies are needed to establish their safety and efficacy, as well as to advance scientific understanding of their clinical potentials. In many cases, incorporation of advanced imaging and IGI techniques into clinical trials remains difficult, is not in-pace with clinical need, and is under supported.
This solicitation will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. The imaging and Image-guided Intervention investigations, if proven successful in these early clinical trials, can then be validated in larger studies via competitive R01 mechanisms, or through clinical trials in the NCI’s Specialized Programs of Research Excellence, Cancer Center or Cooperative Groups.
Applications are due 5 p.m. July 11; Nov. 13; or March 13.
For more information and complete application guidelines, visit http://grants.nih.gov/grants/guide/pa-files/PAR-11-216.html
